Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula I

$$X_{N}$$

wherein X is O or S, R_1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2- 18 F-ethylamino)-thiazol-2-yl or a group of formula (a)

$$R_2$$
 (a)

wherein Y is CH or N, R_2 is NHCH₃, NH¹¹CH₃, N(CH₃)¹¹CH₃, N(CH₃)₂, N(¹¹CH₃)₂, NH(CH₂)_nF, NH(CH₂)_nF, N(CH₃)-(CH₂)_nF, N(CH₃)-(CH₂)_nF, O-(CH₂)_nF, O-(CH₂)_nF, O-(CH₂)_nF, CONH(CH₂)_nF or CONH(CH₂)_n¹⁸F (n being in each case 2 to 4) and R_3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form.

- 2. (Currently amended) A process for the production of a compound of formula I as defined in claim 1 and its <u>acid addition</u> salts, comprising the steps of
- a) for the production of a compound of formula I which contains no ¹¹C or ¹⁸F atom, reacting a compound of formula II

wherein X is as defined in claim 1 and Hal is Cl, Br or I, with 5-(2-fluoro-ethylamino)thiazolyl-2-boronic acid or a compound of formula III

wherein Y and R₃ are as defined above and R'₂ is a group R₂ as defined above which contains no ¹¹C or ¹⁸F atom, or

- b) for the production of a compound of formula I wherein R_1 is 5-(2- 18 F-ethylamino)-thiazol-2-yl, reacting a compound of formula I wherein R_1 is 5-(2-mesyloxy-ethylamino)-thiazol-2-yl or 5-(2-tosyloxy-ethylamino)-thiazol-2-yl with 18 F $^{\odot}$, or
- c) for the production of a compound of formula I wherein R_2 is $NH^{11}CH_3$, $N(CH_3)^{11}CH_3$ or $N(^{11}CH_3)_2$, reacting a compound of formula I wherein R_2 is NH_2 or $NHCH_3$ with $^{11}CH_3I$, or

and recovering the resulting compound of formula I in free base form or in <u>acid addition</u> salt form of an acid addition salt.

- 3. (Original) A composition for labeling histopathological structures in vitro or in vivo, comprising a compound of formula I as defined in claim 1, in free base or acid addition salt form.
- 4. (Withdrawn) A method for labeling histopathological structures in vitro or in vivo, comprising contacting brain tissue with a compound of formula I as defined in claim 1, in free base or acid addition salt form.
- 5. (Withdrawn) A method according to claim 4, for labeling β-amyloid deposits.

- 6. (Withdrawn) A method according to claim 4, comprising administering the compound of formula I to a patient.
- 7. (Withdrawn) A method according to claim 4, comprising the further step of determining whether the compound of formula I labeled the target structure.
- 8. (Withdrawn) A method according to claim 7, comprising observing the target structure labeled with a non-radioactive compound of formula I, using fluorescence microscopy.
- 9. (Withdrawn) A method according to claim 7, comprising observing the target structure labeled with a radioactive compound of formula I, using positron emission tomography (PET).
- 10. (Withdrawn) A method according to claim 4 for diagnosing Alzheimer's disease.
- 11. (Withdrawn) A method according to claim 10, for monitoring the effectiveness of a therapeutic treatment of Alzheimer's disease.
- 12. (Withdrawn) A method according to claim 4, for detecting histopathological hallmarks of Alzheimer's disease.
- 13-15. (Cancelled)
- 16. (New) A package comprising a compound of formula I,

$$X_{N}$$
 R_{1}

wherein X is O or S, R_1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2- 18 F-ethylamino)-thiazol-2-yl or a group of formula (a)

$$R_2$$
 (a)

wherein Y is CH or N, R₂ is NH₂ or NHCH₃, and R₃ is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form,

together with instructions for the production of the compound of formula I wherein R₂ is NH¹¹CH₃, N(CH₃)¹¹CH₃ or N(¹¹CH₃)₂ by reaction of the starting material with freshly prepared ¹¹CH₃I.

17. (New) A package comprising as starting material a compound of formula I,

$$X_{N}$$

wherein X is O or S, R_1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2- 18 F-ethylamino)-thiazol-2-yl or a group of formula (a)

$$R_2$$
 (a)

wherein Y is CH or N, R₂ is NH(CH₂)_nOTs, NH(CH₂)_nOMs, N(CH₃)-(CH₂)_nOTs, N(CH₃)-(CH₂)_nOMs, O-(CH₂)_nOTs, O-(CH₂)_n-OMs, CONH(CH₂)_nOTs or ONH(CH₂)_nOMs (n being in each case 2 to 4), wherein OMs corresponds to mesylate and OTs to tosylate, and R₃ is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form,

together with instructions for the production of the compound of formula I wherein R_2 is NH(CH₂)_n¹⁸F, N(CH₃)-(CH₂)_n¹⁸F, O-(CH₂)_n¹⁸F or CONH(CH₂)_n¹⁸F by a suitable reaction cascade of the starting material with ¹⁸F $^{\Theta}$.